STOCK TITAN
  1. Home
  2. BRPA

Big Rock partners Acquisition (BRPA) Stock Price, News & Analysis

BRPA
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
61 182 sessions, June 9, 2020 to May 24, 2021
Largest daily move
+88% close of May 20, 2021
1-month change
-29.4% closing prices, April 23, 2021 to May 24, 2021

Company Description

BRPA declined 0.6% in the year to May 24, 2021. The last closing price was $24.25.

This page collects what Stock Titan holds for BRPA, including price data and latest news.

Stock Performance

Chart
$24.25
No recent trading
Last close: May 24, 2021
-0.6%
Year to May 24, 2021
-
Market Cap
-
Shares outstanding

Big Rock partners Acquisition (BRPA) closed at $24.25 on May 24, 2021. In the year to May 24, 2021, the price lost 0.6%.

See what a $1,000 investment in BRPA would be worth today

Average down calculator for BRPA

BRPA Metrics & Rankings

May 2021
-37.3%
—
2021
-0.6%
—

Price returns through May 24, 2021. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

View All
—

NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)

acquisition
-11.88%

Big Rock Partners Acquisition Corp. Announces Effectiveness of Registration Statement; Confirms Annual Meeting Date of May 24, 2021 to Approve Proposed Merger with NeuroRx

acquisition
-5.39%

NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia

covid-19
+13.50%

Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team

clinical trial covid-19
-14.15%

NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development

+3.14%

Big Rock Partners Acquisition Corp. Clarifies Procedure for Stockholder Conversions and Urges Stockholders To Vote "For" Extension Amendment Proposal

acquisition
+12.51%

NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19

clinical trial covid-19
+36.33%

NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure

clinical trial covid-19
+8.33%

Neurorx, Inc. and Big Rock Partners Acquisition Corp. Announce Committed $10 Million Pipe to Support Proposed Business Combination

acquisition
+2.26%

NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration

Big Rock partners Acquisition has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include acquisition, covid-19, clinical trial. View all BRPA news →

SEC Filings

No SEC filings available for BRPA.

Frequently Asked Questions

Big Rock partners Acquisition (BRPA) has no recent trading. Its last close was $24.25 on May 24, 2021.